Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05086315




Registration number
NCT05086315
Ethics application status
Date submitted
19/10/2021
Date registered
20/10/2021
Date last updated
23/10/2024

Titles & IDs
Public title
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Scientific title
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Secondary ID [1] 0 0
U1111-1266-7399
Secondary ID [2] 0 0
TCD17197
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Lymphocytic Leukaemia 0 0
Acute Myeloid Leukaemia Refractory 0 0
Myelodysplastic Syndromes 0 0
Blastic Plasmacytoid Dendritic Cell Neoplasia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SAR443579

Experimental: SAR443579 - Dose Escalation: SAR443579 administered intravenously at escalating dose levels.

Dose Expansion: SAR443579 administered intravenously at the recommended dose and schedule determined from the dose escalation.


Treatment: Drugs: SAR443579
Powder for solution for infusion; by IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Escalation Part: Incidence of dose-limiting toxicity (DLT)
Timepoint [1] 0 0
Day 1 to Day 28
Primary outcome [2] 0 0
Japan Cohort C: Incidence of DLT in Japanese participants
Timepoint [2] 0 0
Day 1 to Day 28
Primary outcome [3] 0 0
Expansion/Optimization part (Cohorts A1, A2 & D), AML: Proportion of participants who have a CR + CRh + CRi according to the modified AML IWG 2003 criteria
Timepoint [3] 0 0
Up to 6 months
Primary outcome [4] 0 0
Expansion/Optimization part (Cohort B), MDS: Overall response rate (CR + CR equivalent + PR + CRL + CRh + HI) according to the IWG 2023 MDS response criteria
Timepoint [4] 0 0
Up to 6 months
Secondary outcome [1] 0 0
Expansion/Optimization part - Cohorts A, B and D: Recommended dose for expansion (RDE)
Timepoint [1] 0 0
Up to 12 months
Secondary outcome [2] 0 0
Escalation and Expansion/Optimization parts - Cohorts A, B, C and D: Number of participants with TEAEs
Timepoint [2] 0 0
Up to 30 months
Secondary outcome [3] 0 0
Escalation and Expansion/Optimization parts - Cohorts A, B, C and D: Ctrough
Timepoint [3] 0 0
Day 1 to end of trial (maximum up to 30 months)
Secondary outcome [4] 0 0
Escalation and Expansion/Optimization parts - Cohorts A, B, C and D: Incidence of ADA
Timepoint [4] 0 0
Up to 30 months
Secondary outcome [5] 0 0
Escalation and Expansion/Optimization parts - Japan Cohort C, AML: Rate of CR + CRh + CRi per AML 2003 modified IWG response criteria
Timepoint [5] 0 0
Up to 6 months
Secondary outcome [6] 0 0
Escalation and expansion/Optimization parts - Japan Cohort C, MDS: CR rate and ORR rate per IWG 2023 MDS response criteria for escalation part and ORR rate per IWG 2023
Timepoint [6] 0 0
Up to 6 months
Secondary outcome [7] 0 0
Escalation and Expansion/Optimization parts - Japan Cohort C, B-ALL: Rate of CR + CRh + CRi as defined by National Comprehensive Cancer Network (NCCN)
Timepoint [7] 0 0
Up to 6 months
Secondary outcome [8] 0 0
Expansion/Optimization part - Cohorts A and D: Overall response rate (ORR)
Timepoint [8] 0 0
Up to 6 months
Secondary outcome [9] 0 0
Expansion/Optimization part - Cohorts A and D: Duration of CR + CRh + CRi (Duration of CRc)
Timepoint [9] 0 0
Up to 30 months
Secondary outcome [10] 0 0
Expansion/Optimization part - Cohorts A and D: Duration of CR + CRi + CRh + PR + MLFS (Duration of overall response rate)
Timepoint [10] 0 0
Up to 30 months
Secondary outcome [11] 0 0
Expansion/Optimization part - Cohorts A and D: Alternative CR rate
Timepoint [11] 0 0
Up to 6 months
Secondary outcome [12] 0 0
Expansion/Optimization part - Cohorts A and D: Duration of CR + CRh (Duration of alternative CR)
Timepoint [12] 0 0
Up to 30 months
Secondary outcome [13] 0 0
Expansion/Optimization part - Cohorts A and D: Event-free survival (EFS)
Timepoint [13] 0 0
Up to 6 months
Secondary outcome [14] 0 0
Expansion/Optimization part - Cohorts A and D: Overall survival (OS)
Timepoint [14] 0 0
Up to 30 months
Secondary outcome [15] 0 0
Expansion/Optimization part - Cohorts A and D: Rate of hematopoietic stem cell transplantation (HSCT)
Timepoint [15] 0 0
Up to 30 months
Secondary outcome [16] 0 0
Expansion/Optimization part - Cohorts A and D: Time to treatment failure (TTF)
Timepoint [16] 0 0
Up to 6 months
Secondary outcome [17] 0 0
Expansion/Optimization part - Cohorts A and D: Rate of conversion from transfusion dependence
Timepoint [17] 0 0
Day 0 to Day 56
Secondary outcome [18] 0 0
Expansion/Optimization part - Cohorts A and D: Rate of participants who are transfusion independent at baseline and remain independent during 56-day postbaseline period
Timepoint [18] 0 0
Day 0 to Day 56
Secondary outcome [19] 0 0
Expansion/Optimization part - Cohort B: Alternative CR rate
Timepoint [19] 0 0
Up to 6 months
Secondary outcome [20] 0 0
Expansion/Optimization part - Cohort B: Duration of ORR
Timepoint [20] 0 0
Up to 30 months
Secondary outcome [21] 0 0
Expansion/Optimization part - Cohort B: Event-free survival (EFS)
Timepoint [21] 0 0
Up to 30 months
Secondary outcome [22] 0 0
Expansion/Optimization part - Cohort B: Overall survival (OS)
Timepoint [22] 0 0
Up to 30 months
Secondary outcome [23] 0 0
Expansion/Optimization part - Cohort B: Rate of hematopoietic stem cell transplantation (HSCT)
Timepoint [23] 0 0
Up to 30 months
Secondary outcome [24] 0 0
Expansion/Optimization part - Cohort B: Time to treatment failure (TTF)
Timepoint [24] 0 0
Up to 30 months
Secondary outcome [25] 0 0
Expansion/Optimization part - Cohort B: Duration of alternative CR (CR + CR equivalent + CRL + CRh)
Timepoint [25] 0 0
Up to 30 months
Secondary outcome [26] 0 0
Expansion/Optimization part - Cohort B: Progression free survival (PFS)
Timepoint [26] 0 0
Up to 30 months

Eligibility
Key inclusion criteria
* Participant must be at least 1 year (for France: 2 years) old at the time the trial participant or legal guardian signs the informed consent form and will be assigned as follows:

* Adult arm: aged at least 18 years old.
* Pediatric arm: aged 1 (for France: 2 years) to less than 18 years old.
* Adult and Pediatric Arms: Escalation and Expansion/Optimization Cohorts A1, A2, C, D: Confirmed diagnosis of primary or secondary AML (any subtype) according to World Health Organization (WHO) 2022 classification. Participants with AML must meet one of the following criteria, a), b), c) or d) and are limited to those with no available (or are ineligible) therapy with known clinical benefit.

a) Primary Induction Failure (PIF) AML, defined as disease refractory to one of the following, i or ii.

i) An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens.

ii) For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens, 1 or 2:

1. 4 cycles of hypomethylating agents (HMA) or
2. 2 cycles HMA + venetoclax b) Early relapse (ER) AML, defined as AML in relapse with CR, CRh or CRi duration less than 6 months on prior induction treatment c) Leukemia in first or higher relapse d) For participants aged 1 (for France: 2 years) to less than 18 years old, primary induction failure is defined as disease refractory after two cycles of induction therapy.

* Adult Arm (Escalation and Expansion/Optimization Cohorts B and Japan Cohort C only): Confirmed diagnosis of MDS, meeting the following criteria:

1. intermediate or high-risk category as per a Revised International Prognostic Scoring System (IPSS-R) AND
2. confirmed CD123 + expression status determined by local institutional standards AND
3. limited to those with no available (or are ineligible) therapy with known clinical benefit.
* Pediatric arms escalation part and Japan Cohort C only: Confirmed diagnosis of CD123+ BALL without extramedullary lesions that have no available (or are ineligible) therapy with known clinical benefit. Participants with non-CNS chloromatous disease are not allowed in the study.
* Body weight at least 10 kg.
* Pediatric arm and escalation part only: Confirmed diagnosis of BPDCN according to World Health Organization (WHO) 2022 classification, who have relapsed or refractory disease with no available (or are ineligible) therapy with known clinical benefit.
* Japan participants (Cohort C): Participant must be at least 18 years old at the time the trial participant signs the informed consent form
Minimum age
1 Year
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status greater than 2 (at least 18 years-old). Karnofsky Scale (16 to 17 years-old) less than 50% or Lansky Scale (less than 16 years-old) less than 50%.
* Ongoing or recent (within 5 years) evidence of significant autoimmune disease that requires or required treatment with systemic immunosuppressive treatments, which may suggest a risk for immune-related adverse events. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement or psoriasis that does not require systemic treatment.
* History of an invasive malignancy within the last 3 years prior to first IMP administration that requires active therapy (adjuvant hormonal therapy is allowed) other than the one treated in this study.
* Evidence of active central nervous system leukemia at the time of enrollment as evidenced by cytology or pathology. Except for participants aged 1 (for France: 2 years) to less than 18 years, central nervous system 1 disease (CNS1) and CNS2 disease are allowed.
* Known acquired immunodeficiency syndrome (AIDS-related illnesses) or human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or having active hepatitis B or C infection, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
* Prior treatment with an anti-CD123-directed agent (except for participants with BPDCN in the pediatric arm).
* Prior HSCT with relapse beyond 3 months or prior CAR-T therapy in B-ALL with relapse beyond 2 months may be included only if off immunosuppression for a minimum of 4 weeks and no evidence of GVHD.
* Receiving at the time of first investigational medicinal product (IMP) administration corticosteroid as a concomitant medication with corticosteroid dose more than 10 mg/day of oral prednisone or the equivalent.
* AML, BPDCN, or HR-MDS participants with prior treatment with cellular therapy, eg, chimeric antigen receptor T cell (CAR-T) or chimeric antigen receptor NK cell (CAR-NK). Prior CAR-T therapy is allowed for participants with B-ALL.
* Concurrent treatment with other investigational drugs.
* Pregnant and breast-feeding women.
* History of solid organ transplant, including corneal transplant.
* Average QTc (using the Fridericia correction calculation) greater than 470 millisecond (msec) at screening.
* Pediatric arm only: Participants with known inherited bone marrow failure syndromes (e.g., bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome). Participants with Down syndrome with adequate organ function as per Investigator discretion are allowed to participate in the study.
* Adult arm Expansion/Optimization- Participants with MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), unclassifiable MDS/MPN and therapy-related MDS (t-MDS).
* Confirmed diagnosis of acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML) according to WHO 2022 classification.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/10/2030
Actual
Sample size
Target
169
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Investigational Site Number :0360002 - Melbourne
Recruitment hospital [2] 0 0
Investigational Site Number :0360001 - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
China
State/province [10] 0 0
Tianjin
Country [11] 0 0
China
State/province [11] 0 0
Zhengzhou
Country [12] 0 0
France
State/province [12] 0 0
Marseille
Country [13] 0 0
France
State/province [13] 0 0
Paris
Country [14] 0 0
France
State/province [14] 0 0
Villejuif
Country [15] 0 0
Netherlands
State/province [15] 0 0
Amsterdam
Country [16] 0 0
Netherlands
State/province [16] 0 0
Groningen
Country [17] 0 0
Netherlands
State/province [17] 0 0
Nijmegen
Country [18] 0 0
Netherlands
State/province [18] 0 0
Rotterdam
Country [19] 0 0
Netherlands
State/province [19] 0 0
Utrecht

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.
Trial website
https://clinicaltrials.gov/study/NCT05086315
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Trial Transparency email recommended (Toll free for US & Canada)
Address 0 0
Country 0 0
Phone 0 0
800-633-1610
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05086315